Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

CONNECTED TRANSACTION
PROVISION OF FINANCIAL ASSISTANCE

BACKGROUND

The Board announces that on June 2, 2026 (after trading hours), the Company (as the lender) entered into the Financial Assistance Agreement with Rimag Yuntai and Wuhan Ronggongshe (as the borrowers). Pursuant to the agreement, the Company will provide cash loans to Rimag Yuntai and Wuhan Ronggongshe.

LISTING RULES IMPLICATIONS

As at the date of this announcement, Rimag Yuntai is owned as to 51% and 49% directly by the Company and Shanghai Ronggongshe, respectively. Mr. CHEN Zhaoyang is the chairman of the Board, an executive Director and the chief executive officer of the Company. Mr. CHEN Zhaoyang is able to exercise 10% or more of the voting rights at Rimag Yuntai through Shanghai Ronggongshe, and therefore Rimag Yuntai constitutes a connected subsidiary of the Company under Rule 14A.16 of the Listing Rules. Wuhan Ronggongshe is owned as to 51% and 49% directly by Ganjiang Rimag, a wholly-owned subsidiary of the Company, and Shanghai Ronggongshe, respectively. Mr. CHEN Zhaoyang is able to exercise 10% or more of the voting rights at Wuhan Ronggongshe through Shanghai Ronggongshe, and therefore Wuhan Ronggongshe constitutes a connected subsidiary of the Company under Rule 14A.16 of the Listing Rules. Accordingly, the provision of the financial assistance by the Company to Rimag Yuntai and Wuhan Ronggongshe constitutes a connected transaction of the Company.

Pursuant to Rule 14A.81 of the Listing Rules, a series of connected transactions will be aggregated and treated as a single transaction if they are all entered into or completed within the same 12-month period or are otherwise related. The counterparties to the Financial Assistance and the Previous Financial Assistances are both Rimag Yuntai and Wuhan Ronggongshe, and the nature of the transactions is similar, and therefore they shall be aggregated. As the highest applicable percentage ratio (as defined in Rule 14.07 of the Listing Rules) in respect of the Financial Assistance, on a standalone basis and when aggregated with the Previous Financial Assistances, is more than 0.1% but less than 5%, the Financial Assistance is subject to the reporting and announcement requirements but exempt from the circular and independent Shareholders' approval requirement under Chapter 14A of the Listing Rules.

BACKGROUND

Reference is made to the announcement of the Company dated December 15, 2025 in relation to the entering into of the maximum guarantee agreements by the Company and Shanghai Ronggongshe with XW Bank, respectively. Pursuant to the respective agreements, each of the Company and Shanghai Ronggongshe will provide a joint and several liability guarantee in respect of a credit facility of an aggregate amount of not exceeding RMB50 million to be granted by XW Bank to Rimag Yuntai and Wuhan Ronggongshe (the "**First Financial Assistance**").

Reference is further made to the announcement of the Company dated February 12, 2026 in relation to the entering into of the Loan Facility Agreement by the Company (as the lender) with Rimag Yuntai and Wuhan Ronggongshe (as the borrowers). Pursuant to the agreement, the Company will provide a credit facility of an aggregate amount of not exceeding RMB44 million to Rimag Yuntai and Wuhan Ronggongshe (the "**Second Financial Assistance**", together with the First Financial Assistance, the "**Previous Financial Assistances**").

The Board announces that on June 2, 2026, the Company (as the lender) entered into the Financial Assistance Agreement with Rimag Yuntai and Wuhan Ronggongshe (as the borrowers). Pursuant to the agreement, the Company will provide cash loans of an aggregate amount of not exceeding RMB32 million to Rimag Yuntai and Wuhan Ronggongshe (the "**Financial Assistance**"). The facility represents the total loan limit for Rimag Yuntai and Wuhan Ronggongshe.

THE FINANCIAL ASSISTANCE AGREEMENT

The principal terms of the Financial Assistance Agreement are summarized as follows:

Parties:	The Company (as the lender); Rimag Yuntai (as the borrower); and Wuhan Ronggongshe (as the borrower).
Assistance period:	From the date of signing of the Financial Assistance Agreement until December 29, 2028

Cash loans:

(1) Loan currency: RMB;

(2) Loan interest rate: the annual interest rate is 5.5%;

(3) Loan term: 3 years. For each single loan, the loan term of such loan shall be the period from the date on which the Company actually pays the loan to Rimag Yuntai or Wuhan Ronggongshe until the date of expiry of the 3-year loan term. If Rimag Yuntai or Wuhan Ronggongshe needs to make early repayment for a certain loan, the loan term of such loan shall be the period from the date on which the Company actually pays the loan to Rimag Yuntai or Wuhan Ronggongshe until the date on which Rimag Yuntai or Wuhan Ronggongshe actually repays the loan to the Company, being the actual period of fund occupancy of such loan;

(4) Method of interest calculation: interest shall be calculated on a daily basis, and daily interest rate = annual interest rate/360;

(5) Payment of interest: upon the expiry of each loan term, Rimag Yuntai or Wuhan Ronggongshe shall repay the loan principal to the Company together with the accrued interest under the Financial Assistance Agreement.

Use of loans:

The loans shall be used for the business operations of Rimag Yuntai and Wuhan Ronggongshe. Without the prior written consent of the Company, neither Rimag Yuntai nor Wuhan Ronggongshe may change the use of the loans, including but not limited to using the loans for investments in real estate, equity, or other assets; nor may they use the loans for relending or for any fields or purposes prohibited by the State for production or operation.

Penalty interest:

(1) If Rimag Yuntai or Wuhan Ronggongshe fails to repay all loan principal and interest to the Company in accordance with the Financial Assistance Agreement, liquidated damages shall accrue at the rate of 0.05% per day on the overdue amount. If such default continues for an aggregate of 30 days, the Company shall have the right to declare all loans immediately due and payable.

(2) If Rimag Yuntai or Wuhan Ronggongshe fails to repay the loan principal and interest in full and on time in accordance with the Financial Assistance Agreement, in addition to paying the principal, interest and liquidated damages as agreed, it shall also bear all expenses incurred by the Company in connection with the enforcement of its claims, including but not limited to litigation fees, attorney's fees, property preservation fees, preservation insurance premiums, notarization fees, and all other reasonable expenses payable.

INFORMATION ON THE PARTIES

Information on the Group

The Group is a leading medical group specialized in medical imaging in China and the only operator and manager of a medical imaging platform that provides diversified imaging services and value to the entire medical imaging industry chain in China. The Group is principally engaged in the provision of imaging center services, imaging solution services and digital and intelligent services.

Information on Rimag Yuntai

Rimag Yuntai is a company incorporated under the laws of the PRC with limited liability and is principally engaged in the sales and leasing of medical devices, as well as imaging solutions services of the Group. As at the date of this announcement, the ultimate beneficial owners of Rimag Yuntai are the Company and Mr. CHEN Zhaoyang.

Information on Wuhan Ronggongshe

Wuhan Ronggongshe is a company incorporated under the laws of the PRC with limited liability and is principally engaged in the wholesale and retail of Class I, II, and III medical devices in the medical device trade fields such as hemodialysis, imaging, orthopedics, stomatology, ophthalmology, and obstetrics, and supply chain management, as well as computer technical services. It empowers the development of the medical device industry chain and enjoys a degree of influence and market share in the medical device supply chain business. As at the date of this announcement, the ultimate beneficial owners of Wuhan Ronggongshe are the Company and Mr. CHEN Zhaoyang.

REASONS FOR AND BENEFITS OF ENTERING INTO THE FINANCIAL ASSISTANCE AGREEMENT

The provision of cash loans by the Company to its subsidiaries aims to provide necessary financial support for the development of their empowerment solution services business, satisfy the capital requirements for business operations and expansion, promote the steady growth in business scale, and further strengthen and consolidate their competitive advantages in the market.

The Directors (including the independent non-executive Directors) are of the view that the terms of the Financial Assistance Agreement are on normal commercial terms, fair and reasonable and in the interests of the Company and the Shareholders as a whole. Mr. CHEN Zhaoyang, who has a material interest in the Financial Assistance Agreement and the transactions contemplated thereunder, has abstained from voting on the Board resolution for considering and approving the provision of financial assistance to Rimag Yuntai and Wuhan Ronggongshe.

LISTING RULES IMPLICATIONS

As at the date of this announcement, Rimag Yuntai is owned as to 51% and 49% directly by the Company and Shanghai Ronggongshe, respectively. Mr. CHEN Zhaoyang is the chairman of the Board, an executive Director and the chief executive officer of the Company. Mr. CHEN Zhaoyang is able to exercise 10% or more of the voting rights at Rimag Yuntai through Shanghai Ronggongshe, and therefore Rimag Yuntai constitutes a connected subsidiary of the Company under Rule 14A.16 of the Listing Rules. Wuhan Ronggongshe is owned as to 51% and 49% directly by Ganjiang Rimag, a wholly-owned subsidiary of the Company, and Shanghai Ronggongshe, respectively. Mr. CHEN Zhaoyang is able to exercise 10% or more of the voting rights at Wuhan Ronggongshe through Shanghai Ronggongshe, and therefore Wuhan Ronggongshe constitutes a connected subsidiary of the Company under Rule 14A.16 of the Listing Rules. Accordingly, the provision of the financial assistance by the Company to Rimag Yuntai and Wuhan Ronggongshe constitutes a connected transaction of the Company.

Pursuant to Rule 14A.81 of the Listing Rules, a series of connected transactions will be aggregated and treated as a single transaction if they are all entered into or completed within the same 12-month period or are otherwise related. The counterparties to the Financial Assistance and the Previous Financial Assistances are both Rimag Yuntai and Wuhan Ronggongshe, and the nature of the transactions is similar, and therefore they shall be aggregated. As the highest applicable percentage ratio (as defined in Rule 14.07 of the Listing Rules) in respect of the Financial Assistance, on a standalone basis and when aggregated with the Previous Financial Assistances, is more than 0.1% but less than 5%, the Financial Assistance is subject to the reporting and announcement requirements but exempt from the circular and independent Shareholders' approval requirement under Chapter 14A of the Listing Rules.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

"Board"	the board of Directors of the Company
"China" or "PRC"	the People's Republic of China, which for the purpose of this announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Company" or "our Company"	Jiangxi Rimag Group Co., Ltd. (江西一脈陽光集團股份有限公司), a joint stock company with limited liability established in the PRC and the H Shares of which are listed on the Stock Exchange (stock code: 2522)
"connected subsidiary(ies)"	has the meaning ascribed to it in the Listing Rules

"connected transaction(s)"	has the meaning ascribed to it in the Listing Rules
"Director(s)"	the director(s) of the Company
"Ganjiang Rimag"	Jiangxi Ganjiang New Area Rimag Health Management Limited (江西贛江新區一脈陽光健康管理有限公司), a wholly-owned subsidiary of the Company
"Group"	the Company and its subsidiaries
"H Share(s)"	overseas listed foreign ordinary share(s) in the share capital of our Company with nominal value of RMB1.00 each, which are listed and traded on the Stock Exchange
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Financial Assistance Agreement"	the financial assistance agreement entered into among the Company, Rimag Yuntai and Wuhan Ronggongshe on June 2, 2026
"Rimag Yuntai"	Beijing Rimag Yuntai Medical Devices Co., Ltd. (北京一脈雲泰醫療器械有限公司)
"RMB"	Renminbi, the lawful currency of the PRC
"Shanghai Ronggongshe"	Shanghai Ronggongshe Fanghou Technology Limited (上海融公社芳侯科技有限公司)
"Share(s)"	ordinary shares in the share capital of our Company with a nominal value of RMB1.00 each, including unlisted shares and H Shares
"Shareholder(s)"	holder(s) of the Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules

"Wuhan Ronggongshe"	Wuhan Ronggongshe Medical Equipment Co., Ltd. (武漢融公社醫療器械有限公司)
"XW Bank"	Sichuan XW Bank Co., Ltd. (四川新網銀行股份有限公司)
"%"	per cent

By order of the Board
Jiangxi Rimag Group Co., Ltd.
Mr. CHEN Zhaoyang
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, June 2, 2026

As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. GUO Tao and Mr. MENG Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.